This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ebeling, T. Articles by Salmela, P. I. Search for Related Content PubMed PubMed Citation Articles by Ebeling, T. Articles by Salmela, P. I.

Effect of Multiple Endocrine Neoplasia Type 1 (MEN1) Gene Mutations on Premature Mortality in Familial MEN1 Syndrome with Founder Mutations

Department of Medicine (T.E., P.I.S.), University of Oulu and Oulu University Hospital, and Department of Clinical Genetics (O.V., J.L.), Oulu University Hospital, FIN-90029 Oys, Finland; and Medix Laboratories Ltd. (S.K.), FIN-02630 Espoo, Finland

Address all correspondence and requests for reprints to: Tapani Ebeling, Department of Medicine, Oulu University Hospital, PB 20, FIN-90029 OYS, Finland. E-mail: tapani.ebeling{at}oulu.fi.

Estimation of mortality and the natural course of a disease is usually based on information of carefully studied individuals with or at risk for a specific disease. Genealogical information has rarely been accurate enough for such studies.

With the help of church records and multiple endocrine neoplasia type 1 (MEN1) family information of the two founder MEN1 mutations in Northern Finland (1466del12 and 1657insC), we could trace back common ancestors born in the beginning of the 1700s (1466del12) and approximately 1850 (1657insC) and find 67 probable gene carriers born between 1728 and 1929, which were identified among their offspring. Information was gathered from 34 obligatory MEN1 gene carriers and 31 spouses. The mean age (± SD) of death of affected males (n = 16) was 61.1 ± 12.0 yr vs. 65.8 ± 15.3 yr for unaffected males (n = 16) and for affected females (n = 16) was 67.2 ± 10.7 yr vs. 67.7 ± 14.7 yr for unaffected females (n = 13). The ages of death of the obligatory heterozygotes did not differ from that of the spouses in sex groups or from the sex-matched life expectancy estimates derived from Finnish national statistics. Causes of death differed significantly between female probands and spouses. In conclusion, obligatory MEN1 gene carrier status did not show a harmful effect on survival in this retrospective analysis tracing back to almost 300 yr.

This work was supported by Oulu University Hospital scientific (kevo) program and grants from the Cancer Society of Northern Finland.

Abbreviation: MEN1, Multiple endocrine neoplasia type 1.

This article has been cited by other articles:

				O Vierimaa, T M L Ebeling, S Kytola, R Bloigu, E Eloranta, J Salmi, E Korpi-Hyovalti, L Niskanen, A Orvola, E Elovaara, et al. Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype phenotype correlation Eur. J. Endocrinol., September 1, 2007; 157(3): 285 - 294. [Abstract] [Full Text] [PDF]